Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Guanidinoacetate N-methyltransferase is a key enzyme in the biosynthesis of creatine, catalyzing the transfer of a methyl group from S-adenosylmethionine to guanidinoacetate to produce creatine, a molecule critical for energy storage and utilization in cells, especially neurons and myocytes[1][2][3]. Its deficiency leads to a rare but treatable neurometabolic disorder characterized by mental retardation, movement disorder, seizures, and muscle hypotonia; creatine supplementation can ameliorate many symptoms[3][5]. GAMT is predominantly expressed in the liver, brain, and certain glial cells (notably oligodendrocytes), and supports cellular energy metabolism and neurodevelopment. GAMT's function links methyl group metabolism to ATP buffering, highlighting its fundamental biological importance[1][4].
Creatine supplementation: supplies missing creatine, bypassing the metabolic block caused by GAMT deficiency
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Guanidinoacetate N-methyltransferase (GAMT).